J. F. de Vries

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.

J. Aerts, P. Baas, V. van der Noort, 2019, JAMA oncology.

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

E. Thunnissen, P. Baas, H. Klomp, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing

J. Falkenburg, M. Heemskerk, R. Willemze, 2007, Haematologica.

The potential use of basigin (CD147) as a prognostic marker in B‐cell precursor acute lymphoblastic leukaemia

J. V. van Dongen, V. V. D. van der Velden, J. te Marvelde, 2010, British journal of haematology.

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

P. Baas, V. van der Noort, K. Monkhorst, 2019, The Lancet. Respiratory medicine.

The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells.

J. Falkenburg, R. Willemze, R. Barge, 2006, Haematologica.

Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria

J. Falkenburg, M. Heemskerk, R. Willemze, 2006, Apoptosis.

Genomic organisation and chromosomal localisation of two members of the KCND ion channel family, KCND2 and KCND3

A. Moorman, A. Wilde, C. Bezzina, 2000, Human Genetics.

OA04.06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)

P. Baas, F. Lalezari, J. Burgers, 2022, Journal of Thoracic Oncology.

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.

P. Baas, J. Burgers, K. Monkhorst, 2023, The Lancet. Oncology.